Javascript must be enabled to continue!
820 New Insights into the Genomic Landscape of Skull Base Meningiomas
View through CrossRef
INTRODUCTION:
The management of skull base meningiomas is challenging due to their complexity and proximity to crucial nearby structures. The identification of oncogenic mutations has provided further insights into the tumorigenesis of meningioma and the possibility of targeted therapy.
METHODS:
Tissue samples were collected from 71 patients diagnosed with meningioma from 2008 to 2016. Tissues were treated and archived as formalin-fixed paraffin-embedded (FFPE). Samples were subjected to targeted sequencing using a customized gene panel.
RESULTS:
The study cohort comprised 71 patients with histologically proven meningioma (grades I, II, and III) .The median patient age was 54.8 years (range 27-96 years). Most of the patients were female (51/71, 72.82%), while 19/71 (27.14%) were male. 56/71 patients had grade I (80.0%), 13/71 (18.57%) had grade II and 1/71 (1.428%) had grade III tumors. A total of 51/71 of the tumors were found in the skull base (72.82%). 22/71 (31.42%) of the tumors were meningothelial, 6/71 (8.57%) were atypical, 6/71 (8.57%) were transitional, 3/71 (4.28) were secretory, and 2/71 (2.86%) were chordoid. We detected an average of 1.56 ± 1.07 genomic alterations (GAs) per patient. the most common mutations were in NF2 (52/71), PIK3CA (22/71), FGFR3 (13/71), SMO (11/71) and AKT1 (10/71), with Tertp (1/71) mutations being the least frequent. The NF2-positive tumors were predominantly of grade I 43/52 (82.69%) with lower rates of recurrence (7/52, 13.41%) in tumors harboring NF2 mutations compared to tumor harboring non-NF2 mutations (8/18, 44.44%). Single FGFR3 mutations reported in three patients, all had WHO grade I tumors, with no recurrence in our cohort.
CONCLUSIONS:
This cohort focusing skull base meningiomas, highlights a range of mutations outside the known cancer driver NF2 that may be linked to meningioma prognosis. Among our findings were the identification of a rare TERTp mutation and the first report of FGFR3 mutations that may represent biomarkers for the identification of skull base meningioma patients with a favorable prognosis. Taken together, these findings highlight how genetic profiling can guide optimal treatment strategies, prognostic prediction, and patient management for skull meningioma.
Title: 820 New Insights into the Genomic Landscape of Skull Base Meningiomas
Description:
INTRODUCTION:
The management of skull base meningiomas is challenging due to their complexity and proximity to crucial nearby structures.
The identification of oncogenic mutations has provided further insights into the tumorigenesis of meningioma and the possibility of targeted therapy.
METHODS:
Tissue samples were collected from 71 patients diagnosed with meningioma from 2008 to 2016.
Tissues were treated and archived as formalin-fixed paraffin-embedded (FFPE).
Samples were subjected to targeted sequencing using a customized gene panel.
RESULTS:
The study cohort comprised 71 patients with histologically proven meningioma (grades I, II, and III) .
The median patient age was 54.
8 years (range 27-96 years).
Most of the patients were female (51/71, 72.
82%), while 19/71 (27.
14%) were male.
56/71 patients had grade I (80.
0%), 13/71 (18.
57%) had grade II and 1/71 (1.
428%) had grade III tumors.
A total of 51/71 of the tumors were found in the skull base (72.
82%).
22/71 (31.
42%) of the tumors were meningothelial, 6/71 (8.
57%) were atypical, 6/71 (8.
57%) were transitional, 3/71 (4.
28) were secretory, and 2/71 (2.
86%) were chordoid.
We detected an average of 1.
56 ± 1.
07 genomic alterations (GAs) per patient.
the most common mutations were in NF2 (52/71), PIK3CA (22/71), FGFR3 (13/71), SMO (11/71) and AKT1 (10/71), with Tertp (1/71) mutations being the least frequent.
The NF2-positive tumors were predominantly of grade I 43/52 (82.
69%) with lower rates of recurrence (7/52, 13.
41%) in tumors harboring NF2 mutations compared to tumor harboring non-NF2 mutations (8/18, 44.
44%).
Single FGFR3 mutations reported in three patients, all had WHO grade I tumors, with no recurrence in our cohort.
CONCLUSIONS:
This cohort focusing skull base meningiomas, highlights a range of mutations outside the known cancer driver NF2 that may be linked to meningioma prognosis.
Among our findings were the identification of a rare TERTp mutation and the first report of FGFR3 mutations that may represent biomarkers for the identification of skull base meningioma patients with a favorable prognosis.
Taken together, these findings highlight how genetic profiling can guide optimal treatment strategies, prognostic prediction, and patient management for skull meningioma.
Related Results
The extended pterional approach for midline anterior skull base meningiomas
The extended pterional approach for midline anterior skull base meningiomas
Background: Various surgical approaches for the management of midline anterior skull base meningiomas exist in the literature. The main surgeon target is proper selection the appro...
Effect of skull porosity on ultrasound transmission and wave mode conversion at large incidence angles
Effect of skull porosity on ultrasound transmission and wave mode conversion at large incidence angles
AbstractBackgroundTranscranial ultrasound imaging and therapy depend on the efficient transmission of acoustic energy through the skull. Multiple previous studies have concluded th...
Surgical challenges and outcome of endoscopic endonasal approaches in the management of recurrent pituitary adenomas
Surgical challenges and outcome of endoscopic endonasal approaches in the management of recurrent pituitary adenomas
Background: Various surgical approaches for the management of midline anterior skull base meningiomas exist in the literature. The main surgeon target is proper selection the appro...
Microsurgical resection of skull base meningioma Operative Nuances, Challenges, and Outcome
Microsurgical resection of skull base meningioma Operative Nuances, Challenges, and Outcome
Objective: Skull base meningiomas represent a distinct subgroup of intracranial tumours because of their proximity to cranial nerves, major vascular structures, and the brainstem. ...
Altered O-linked glycosylation in benign and malignant meningiomas
Altered O-linked glycosylation in benign and malignant meningiomas
Background
Changes in protein glycosylation have been reported in various diseases, including cancer; however, the consequences of altered glycosylation in meningiomas remains unde...
EPCO-29. GENOMIC PROFILING OF SPORADIC MULTIPLE MENINGIOMAS
EPCO-29. GENOMIC PROFILING OF SPORADIC MULTIPLE MENINGIOMAS
Abstract
INTRODUCTION
In rare cases, sporadic meningiomas can occur as multiple tumors in the same patient without a known germl...
374 Cell Cycle as a Biological Marker of Aggressiveness and Therapeutic Target in Meningiomas
374 Cell Cycle as a Biological Marker of Aggressiveness and Therapeutic Target in Meningiomas
INTRODUCTION:
Meningiomas are the most common intracranial tumors, accounting for 36% of cases. The World Health Organization (WHO) classifies these tumors into three h...

